| EDR | EDR % | Clinician record | Clinician record % | Self-report | Self-report % | Master List | Master List % |
---|---|---|---|---|---|---|---|---|
Any vitamins and supplementsa | 173 | 17.9% | 815 | 84.3% | 759 | 78.5% | 937 | 96.9% |
Any ARTb | 397 | 84.1% | 283 | 56.0% | 434 | 91.9% | 472 | 100% |
1st linec | 374 | 79.2% | 265 | 56.1% | 404 | 85.6% | 448 | 94.9% |
2nd linec | 25 | 5.3% | 18 | 3..8% | 30 | 6.3% | 34 | 7.2% |
STI syndromic treatmentd | 45 | 4.7% | 38 | 3.9% | 73 | 7.6% | 130 | 13.4% |
Metronidazole (P01AB01) | 36 | 3.7% | 32 | 3.3% | 71 | 7.3% | 116 | 12.0% |
Ceftriaxone (J01DD04) | 0 | 0.0% | 33 | 3.4% | 4 | 0.4% | 36 | 3.7% |
Benzathine penicillin (J01CE08)e | 0 | 0.0% | 11 | 1.1% | 25 | 2.6% | 35 | 3.6% |
Treatment for TBf | 4 | 0.4% | 0 | 0.0% | 4 | 0.4% | 7 | 0.7% |
Isoniazid (J04AC01) as TBPT | 166 | 17.2% | 3 | 0.3% | 7 | 0.7% | 167 | 17.3% |
Influenza vaccine (J07BB01) | 0 | 0.0% | 225 | 23.3% | 3 | 0.3% | 226 | 23.4% |
Treatment for diabetes mellitus (A10) | 13 | 1.3% | 2 | 0.2% | 4 | 0.4% | 13 | 1.3% |
Glucose lowering drugs excl. insuling | 13 | 1.3% | 2 | 0.2% | 4 | 0.4% | 13 | 1.3% |
Insulins (A10A) | 8 | 0.8% | 0 | 0.0% | 0 | 0.0% | 8 | 0.8% |
Anti-epileptic treatments (N03) | ||||||||
Phenytoin (N03AB02) | 1 | 0.10% | 1 | 0.10% | 0 | 0.0% | 1 | 0.1% |
Sodium valproate (N03AG01) | 0 | 0.0% | 0 | 0.0% | 1 | 0.1% | 1 | 0.1% |
Psycholeptics (N05) and anti-depressants (N06) | ||||||||
Haloperidol (N05AA01) | 1 | 0.1% | 0 | 0.0% | 0 | 0.0% | 1 | 0.1% |
Chlorpromazine (N05AD01) | 2 | 0.2% | 0 | 0.0% | 0 | 0.0% | 2 | 0.2% |
Lithium (N05AN01) | 1 | 0.1% | 0 | 0.0% | 0 | 0.0% | 1 | 0.1% |
Risperidone (N05AX08) | 3 | 0.3% | 0 | 0.1% | 2 | 0.2% | 4 | 0.4% |
Fluoxetine (N06AA09) | 3 | 0.3% | 0 | 0.0% | 1 | 0.1% | 4 | 0.4% |
Amitriptyline (N06AB03) | 1 | 0.1% | 1 | 0.1% | 1 | 0.1% | 3 | 0.3% |
Mianserin (N06AX03) | 1 | 0.1% | 0 | 0.0% | 0 | 0.0% | 1 | 0.1% |